30-day average of 22 articles Β· scale β100 to +100
Across 22 scored articles from Oct 16 to Nov 14, 2026 (UTC),
the average sentiment of Intuitive Surgical news is Somewhat Bullish (+37)
on a scale from β100 to +100.
That is down 7 points from the previous 30 days (+44).
π Worldwide procedures grew 14%, with international markets up 20%.
π U.S. da Vinci procedure growth slowed to 10% in Q3.
Slightly Bullish +20
A $5.9 Billion Fund Is Betting Big on Intuitive Surgical
AI-generated analysis
Key insights
π Intuitive Surgical's U.S. da Vinci procedure growth slowed to 10% in Q3, the lowest level since the COVID-19 pandemic.
π Worldwide da Vinci procedures grew 14% in Q3, with international markets expanding at a robust 20% rate.
π° The company placed 546 da Vinci systems in the third quarter, up from 427 placements a year earlier.
βοΈ Intuitive plans to reduce instrument and accessory revenue per procedure by 3% to 5% to win high-volume benign surgeries.
π Valuation compression has pushed the stock to 37x forward earnings, down from a five-year average of 54x.
π The consensus analyst price target fell from $593 to $487 following recent operational and financial data.
πΌ GuardCap Asset Management opened a new position in ISRG with 167,863 shares worth $68 million in Q3.
π Analysts expect normalized EPS to grow from $8.93 in 2025 to $14.04 by 2028.
π The next major catalyst is the fourth-quarter report expected early next year regarding U.S. growth trends.
π Bullish signals
πIntuitive Surgical achieved a 22% revenue increase and 14% worldwide procedure growth in Q3, driven by strong international expansion.
π°The company successfully placed 546 da Vinci systems in the third quarter, demonstrating continued hospital adoption despite domestic headwinds.
πAnalysts project normalized earnings per share to rise significantly from $8.93 in 2025 to $14.04 by 2028.
π Risk factors
πU.S. da Vinci procedure growth slowed to 10% in Q3, the lowest rate seen since the COVID-19 pandemic.
βοΈThe company plans to cut instrument and accessory revenue per procedure by 3% to 5%, which will temporarily reduce revenue per case before volume gains materialize.
πValuation compression has driven the stock price down to 37x forward earnings, well below its five-year average of 54x.
Article
Intuitive Surgical (ISRG) recently faced headwinds as U.S. da Vinci procedure growth slowed to 10% in the third quarter, marking its lowest rate since the COVID-19 pandemic. Despite this domestic slowdown, the company reported a 22% revenue increase and 14% worldwide procedure growth, driven by strong international expansion with 20% growth outside the U.S. Additionally, Intuitive successfully placed 546 da Vinci systems in the third quarter, an increase from 427 a year prior.
To capture more high-volume benign surgeries, Intuitive Surgical plans to cut instrument and accessory revenue per procedure by 3% to 5%. This strategic pricing adjustment has caused the stock to trade at 37x forward earnings, significantly below its five-year average of 54x. Consequently, the consensus analyst price target has decreased from $593 a year ago to $487, though this still implies potential upside from recent lows.
GuardCap Asset Management, which oversees $5.9 billion in assets, initiated a new position in Intuitive Surgical during the third quarter, purchasing 167,863 shares worth approximately $68 million. This investment represents 4.7% of GuardCap's U.S. stock holdings and is its largest new or added position for the period. Analysts project normalized earnings per share to rise from $8.93 in 2025 to $14.04 by 2028, suggesting long-term growth potential despite current valuation compression.
The company's next critical test will be its fourth-quarter report early next year, which is expected to provide clarity on U.S. procedure growth trends for 2027. Investors are closely watching whether the domestic slowdown persists or if international momentum can offset any further declines in the core U.S. market.
Sector and industry come from company profile data. Sentiment is the AI score of the news articles on this page, averaged per day. Not investment advice.
Intuitive Surgical (ISRG) recently faced headwinds as U.S. da Vinci procedure growth slowed to 10% in the third quarter, marking its lowest rate since the COVID-19 pandemic. Despite this domestic slowdown, the company reported a 22% revenue increase and 14% worldwide procedure growth, driven by strong international expansion with 20% growth outside the U.S. Additionally, Intuitive successfully placed 546 da Vinci systems in the third quarter, an increase from 427 a year prior.
To capture more high-volume benign surgeries, Intuitive Surgical plans to cut instrument and accessory revenue per procedure by 3% to 5%. This strategic pricing adjustment has caused the stock to trade at 37x forward earnings, significantly below its five-year average of 54x. Consequently, the consensus analyst price target has decreased from $593 a year ago to $487, though this still implies potential upside from recent lows.
GuardCap Asset Management, which oversees $5.9 billion in assets, initiated a new position in Intuitive Surgical during the third quarter, purchasing 167,863 shares worth approximately $68 million. This investment represents 4.7% of GuardCap's U.S. stock holdings and is its largest new or added position for the period. Analysts project normalized earnings per share to rise from $8.93 in 2025 to $14.04 by 2028, suggesting long-term growth potential despite current valuation compression.
The company's next critical test will be its fourth-quarter report early next year, which is expected to provide clarity on U.S. procedure growth trends for 2027. Investors are closely watching whether the domestic slowdown persists or if international momentum can offset any further declines in the core U.S. market.
π U.S. da Vinci procedure growth slowed to 10% in Q3.
π Worldwide procedures grew 14%, with international markets up 20%.
π° Placed 546 systems in Q3, a 28% increase year-over-year.
βοΈ Plans to reduce revenue per procedure by 3-5% for benign surgeries.
π Stock valuation compressed to 37x forward earnings from 54x average.
π Intuitive Surgical's U.S. da Vinci procedure growth slowed to 10% in Q3, the lowest level since the COVID-19 pandemic.
π Worldwide da Vinci procedures grew 14% in Q3, with international markets expanding at a robust 20% rate.
π° The company placed 546 da Vinci systems in the third quarter, up from 427 placements a year earlier.
βοΈ Intuitive plans to reduce instrument and accessory revenue per procedure by 3% to 5% to win high-volume benign surgeries.
π Valuation compression has pushed the stock to 37x forward earnings, down from a five-year average of 54x.
π The consensus analyst price target fell from $593 to $487 following recent operational and financial data.
πΌ GuardCap Asset Management opened a new position in ISRG with 167,863 shares worth $68 million in Q3.
π Analysts expect normalized EPS to grow from $8.93 in 2025 to $14.04 by 2028.
π The next major catalyst is the fourth-quarter report expected early next year regarding U.S. growth trends.
Bullish Signals
Revenue grew 22% and procedures rose 14% in Q3.
Risk Factors
U.S. da Vinci procedure growth slowed to 10% in Q3.
Plans to cut instrument revenue per procedure by 3-5%.
Valuation compressed to 37x forward earnings vs 54x avg.
Bullish Signals
Intuitive Surgical achieved a 22% revenue increase and 14% worldwide procedure growth in Q3, driven by strong international expansion.
The company successfully placed 546 da Vinci systems in the third quarter, demonstrating continued hospital adoption despite domestic headwinds.
Analysts project normalized earnings per share to rise significantly from $8.93 in 2025 to $14.04 by 2028.
Risk Factors
U.S. da Vinci procedure growth slowed to 10% in Q3, the lowest rate seen since the COVID-19 pandemic.
The company plans to cut instrument and accessory revenue per procedure by 3% to 5%, which will temporarily reduce revenue per case before volume gains materialize.
Valuation compression has driven the stock price down to 37x forward earnings, well below its five-year average of 54x.
Intuitive Surgical announced the appointment of Aaron Martin as an independent director to its board of directors, effective January 1, 2027. Martin brings significant expertise from his previous roles at Humana, Amazon Healthcare, and Providence St. Joseph Health, specifically focusing on payer operations, digital health, and health-system leadership.
This governance move is designed to deepen the board's collective knowledge regarding healthcare technology, insurance dynamics, and relationships with major health systems. The company frames this addition as a strategic step to support broader access to minimally invasive care globally, leveraging Martin's background in overseeing strategy and financial performance within large insurance portfolios.
The appointment expands the board from 10 to 11 directors but is explicitly characterized by management as a governance enhancement rather than a revision to product roadmaps or financial guidance. While Intuitive Surgical stock traded at 399.20 euros on November 12, 2026, reflecting a slight decline from the previous session, the news itself represents a neutral-to-positive structural development focused on long-term strategic oversight and market access.
Martin will serve on the enterprise leadership team of Humana prior to joining Intuitive Surgical, where he managed strategy across the insurer's portfolio. His inclusion aims to provide the board with diverse perspectives on care pathways and payer relationships, which are critical for the company's continued growth in the minimally invasive surgery sector.
π ISRG adds independent director Aaron Martin effective January 1, 2027.
π€ New director brings expertise from Humana, Amazon Healthcare, and Providence.
π₯ Board size expands to 11 directors with enhanced payer oversight.
π‘ Management cites strategic deepening of healthcare technology and insurance oversight.
π Director aims to expand global access via industry connections.
π Intuitive Surgical will add Aaron Martin as an independent director to its board of directors starting January 1, 2027.
π€ The new appointee brings extensive experience from Humana, Amazon Healthcare, and Providence St. Joseph Health.
π₯ The addition aims to strengthen the board's expertise in payer operations, digital health, and health-system leadership.
π This governance change expands the board size from 10 to 11 directors without altering current financial guidance.
π‘ Management views the appointment as a strategic step to deepen oversight of healthcare technology and insurance dynamics.
π Martin expects to contribute to expanding global access to minimally invasive care through his industry connections.
π Intuitive Surgical stock traded at 399.20 euros on November 12, 2026, down 1.15% from the prior session's close.
π The appointment connects board oversight directly with payer operations and relationships with major health systems.
Bullish Signals
Board adds director with payer and digital health expertise.
New member enhances strategic view on care pathways.
Bullish Signals
Intuitive Surgical is strengthening its corporate governance by adding a director with deep expertise in payer operations, digital health, and health-system leadership.
The new board member brings experience from Humana, Amazon Healthcare, and Providence St. Joseph Health, enhancing the company's strategic perspective on care pathways and market access.
Intuitive Surgical (ISRG) sees its fair value estimate rise from approximately US$476.34 to roughly US$486.57 per share, driven by a mixed but ultimately bullish analyst narrative following Q3 results. Major financial institutions including BofA, Barclays, JPMorgan, and Leerink have lifted their price targets, citing robust system placements for the da Vinci 5 platform and strong procedure growth trends outside the United States as key drivers of future revenue.
Despite the positive fair value adjustment, analysts highlight specific headwinds that temper expectations. Wells Fargo notes Q3 revenue of US$3.05 billion and non-GAAP EPS of US$3.00, both beating consensus, but warns that management's quantified pricing actions for 2027 instruments are intended to support adoption while potentially capping overall revenue per procedure impact. Several firms, including RBC and Mizuho, flag slowing U.S. procedure growth and policy-related volume pressures as significant concerns.
Valuation assumptions have shifted slightly downward alongside the price target increase, reflecting a more cautious outlook on long-term margins and multiples. The annual revenue growth assumption has decreased from 11.93% to 11.74%, while the net profit margin expectation moved down from 30.72% to 29.76%. Additionally, the future P/E multiple was revised lower from 43.52x to 40.75x, indicating that while the stock price is expected to rise, the market is pricing in slightly slower growth and tighter profitability over the coming years.
π Fair value estimate rose to US$486.57 on strong Q3 placements.
π° Q3 revenue hit US$3.05B and EPS reached US$3.00, beating consensus.
π U.S. procedure growth slowing and policy pressures pose key risks.
π Revenue growth assumption lowered to 11.74% with margin expectations down.
π Intuitive Surgical's fair value estimate increased from US$476.34 to roughly US$486.57 per share following a mixed but net-positive analyst revision cycle.
π Major firms including BofA, Barclays, JPMorgan, and Leerink lifted price targets citing strong Q3 system placements and confidence in procedure growth over time.
π RBC and Barclays highlight robust da Vinci 5 system placements and steady procedure trends outside the U.S. as key supports for the company's growth runway.
π° Wells Fargo reported Q3 revenue of US$3.05 billion and non-GAAP EPS of US$3.00, both exceeding analyst consensus expectations.
βοΈ Management's quantified 2027 pricing actions on instruments are viewed as a strategy to support adoption while keeping overall revenue per procedure impact in check.
π Multiple analysts flag slowing U.S. procedure growth and policy-related volume pressures as key risks, particularly with high investor expectations already priced in.
π The annual revenue growth assumption was revised down from 11.93% to 11.74%, reflecting a more conservative long-term outlook.
πΈ Net profit margin expectations decreased from 30.72% to 29.76% as analysts adjust for potential margin compression in the sector.
π The future P/E multiple expectation was lowered from 43.52x to 40.75x, suggesting a shift in valuation multiples despite the higher price target.
β οΈ Risks include new soft tissue robotic competitors, remanufactured instruments, and budget pressures in markets like China and parts of Europe.
Bullish Signals
Analysts lifted targets citing solid Q3 results and strong system placement strength.
Robust da Vinci 5 placements support future expansion outside the U.S.
Q3 revenue of US$3.05B and EPS of US$3.00 beat consensus.
Capital demand supports growth runway in ambulatory surgery centers.
Risk Factors
Slowing U.S. procedure growth concerns analysts.
Policy volume pressures weigh on near-term performance.
Sector pause risk until 2027 estimates hold.
Revenue growth assumption revised down to 11.74%.
Net profit margin lowered from 30.72%.
Bullish Signals
Major analysts including BofA, Barclays, JPMorgan, and Leerink lifted price targets citing solid Q3 results and strong system placement strength.
RBC and Barclays highlight robust da Vinci 5 system placements and steady procedure growth trends outside the U.S. as key supports for future expansion.
Wells Fargo noted Q3 revenue of US$3.05 billion and non-GAAP EPS of US$3.00, both beating consensus expectations.
Leerink points to capital demand and a focus on net new system growth in ambulatory surgery centers as key supports for the company's growth runway.
Risk Factors
Multiple analysts flag slowing U.S. procedure growth and sluggish procedures as a key concern, especially with high investor expectations already reflected in the stock.
Mizuho cites ongoing procedure headwinds and policy-related volume pressures that could weigh on near-term performance.
BofA and BTIG reference the risk that the sector may see a pause until investors gain confidence that lower 2027 estimates are achievable.
The annual revenue growth assumption was revised down from 11.93% to 11.74%, indicating a moderation in expected expansion rates.
Net profit margin expectations were lowered from 30.72% to 29.76%, suggesting potential pressure on profitability margins.
Intuitive Surgical, Inc. (ISRG) shares have underperformed the Medical β Instruments industry over the past year, dropping 21.4% compared to a 3.1% gain for the sector. Zacks analysts attribute this weakness to moderating growth in U.S. procedures, specifically weak volumes in bariatric surgery, and intensifying competition alongside pricing pressures within the Chinese market.
The company faces potential margin headwinds from tariffs, shifts in product mix, hospital budget constraints, and the extended-use nature of its instruments. Despite these near-term challenges, the analyst highlights ISRG's durable growth drivers, including its broad robotic platform, an expanding installed base, and a recurring revenue model that supports long-term financial stability.
Long-term prospects for Intuitive Surgical are bolstered by the adoption of new systems like Da Vinci 5, SP, and Ion. Healthy demand for procedures and continued digital innovation further strengthen the company's strategic position, offering attractive growth opportunities despite current underperformance relative to industry peers.
π ISRG shares underperformed sector with -21.4% return vs +3.1%.
β οΈ Risks include moderating U.S. procedures and weak bariatric volumes.
π¨π³ China competition and pricing pressures weigh on international margins.
π° Tariffs and budget constraints could negatively impact profit margins.
π€ Durable growth supported by broad robotic platform and installed base.
π ISRG shares have underperformed the Medical β Instruments industry over the past year with a -21.4% return versus +3.1% for the sector.
β οΈ The company faces specific risks including moderating U.S. procedure growth and weak bariatric volumes impacting revenue.
π¨π³ Intensifying competition and pricing pressures in China are weighing on ISRG's international expansion and margins.
π° External factors such as tariffs, hospital budget constraints, and extended-use instruments could negatively impact profit margins.
π€ ISRG maintains a durable growth foundation supported by its broad robotic platform and expanding installed base.
π΅ The company benefits from a recurring revenue model that provides financial stability and predictable cash flows.
π Adoption of new systems including Da Vinci 5, SP, and Ion strengthens the long-term product pipeline.
π Healthy underlying procedure demand continues to support the core business despite recent stock price weakness.
Intuitive Surgical reported placing 546 new da Vinci surgical robots in the third quarter of 2026, marking a significant increase in hardware deployments despite a notable decline in its stock price of approximately 20% during the same period.
The company's revenue model is heavily anchored in recurring sales of instruments and services rather than one-time hardware sales. This strategy ensures that as the global installed base grows by 12%, Intuitive Surgical benefits from sustained utilization of existing systems, driving consistent cash flow.
With surgical procedures increasing by 15% alongside the expansion of its installed footprint, the company is establishing a sustainable business model that supports long-term growth. The divergence between stock performance and operational metrics highlights strong underlying demand for the platform despite market volatility.
π Intuitive Surgical placed 546 new da Vinci robots in Q3 2026.
π ISRG stock fell approximately 20% during the third quarter of 2026.
π° Revenue relies heavily on recurring instrument and service sales.
π Global installed base grew by 12%, showing strong market penetration.
π₯ Surgical procedures increased by 15%, reflecting growing system demand.
π Intuitive Surgical placed 546 new da Vinci robots in Q3 2026, representing a significant increase in hardware adoption.
π The company's stock price fell approximately 20% during the third quarter of 2026.
π° Revenue relies heavily on recurring sales of instruments and services rather than new hardware sales.
π The global installed base grew by 12%, indicating strong market penetration and system utilization.
π₯ Surgical procedures increased by 15%, reflecting growing demand for the company's robotic surgery systems.
π The business model is sustainable due to high utilization of existing systems supporting long-term growth.
Bullish Signals
Intuitive Surgical placed 546 new da Vinci robots in Q3 2026.
Risk Factors
Stock price dropped ~20% in Q3 2026.
Bullish Signals
Intuitive Surgical placed 546 new da Vinci robots in Q3 2026, a significant increase that demonstrates strong hardware demand.
The global installed base grew by 12%, providing a foundation for recurring revenue from instruments and services.
Surgical procedures rose by 15%, indicating expanding utilization of existing systems and a sustainable business model.
Revenue is driven by recurring sales of instruments and services rather than one-time hardware sales, ensuring stable cash flow.
Risk Factors
The stock price dropped approximately 20% in Q3 2026, indicating short-term market volatility or investor concerns despite operational strength.
Intuitive Surgical has sold a Sunnyvale office and R&D building to Graymark Capital for approximately $36 million, a transaction reported by The Real Deal and Hoodline. This sale price represents roughly double the property's tax value, marking a significant departure from Intuitive Surgical's recent history of acquiring buildings near its Sunnyvale headquarters.
This real estate move signals a notable strategic shift for the robotics manufacturer, which has spent years purchasing properties in the area rather than divesting them. The transaction involves an owner-occupier selling to an investor, suggesting that lease terms and specific space requirements for R&D tenants are driving the deal despite the premium paid over assessed value.
Industry observers note that Graymark Capital has been actively adding office stock in Sunnyvale, indicating strong demand from investors willing to pay premiums for spaces suitable for research and development. While the exact address and square footage remain unconfirmed by independent sources pending county recorder details, the sale highlights evolving real estate dynamics in the South Bay tech sector.
The broader context includes rising commercial rent trends in the San Francisco metro area, which saw an 11.8% year-over-year increase to about $3,445 per month as of September 2026. This specific asset liquidation by Intuitive Surgical provides a data point on how major tech firms are managing their physical footprint and capital allocation strategies in the current market.
π’ Intuitive Surgical sold Sunnyvale R&D building for $36M to Graymark Capital.
π° Sale price is roughly double the property's assessed tax value.
π Divestiture marks strategic shift from previous local real estate acquisitions.
π Graymark pays premium for Sunnyvale space suitable for R&D tenants.
ποΈ Transaction reflects rising commercial rents in San Francisco Bay Area.
π’ Intuitive Surgical sold a Sunnyvale office and R&D building to Graymark Capital for approximately $36 million.
π° The sale price is reported to be roughly double the property's assessed tax value.
π This divestiture marks a strategic shift from Intuitive Surgical's previous pattern of acquiring local real estate.
π Graymark Capital, an investor firm, is paying a premium for space suitable for R&D tenants in Sunnyvale.
π The transaction involves an owner-occupier selling to an external investor, making lease terms critical.
ποΈ The sale reflects broader real estate dynamics and rising commercial rents in the San Francisco Bay Area.
Bullish Signals
Sold non-core asset for $36M cash.
Property sold at double tax value.
Risk Factors
Sold R&D building, reducing owned footprint and expansion flexibility.
Divesting real estate signals pivot away from property ownership.
Bullish Signals
Intuitive Surgical successfully liquidated a non-core asset for approximately $36 million, generating significant cash proceeds from its Sunnyvale real estate portfolio.
The company's willingness to sell a property at double its tax value indicates strong market demand for its location and potentially favorable terms for the buyer.
Risk Factors
The sale of an R&D building near its headquarters represents a reduction in Intuitive Surgical's owned physical footprint, potentially limiting future expansion flexibility without new acquisitions.
Divesting real estate assets may signal a strategic pivot away from owning property to focus capital on core robotics operations or other investments.
Company updateLeadership changeAI-generated analysis
Intuitive Surgical (ISRG) recently expanded its board to include Aaron Martin, a former Amazon healthcare executive and current President of Insurance at Humana. This appointment is viewed as a strategic move to strengthen the company's long-term positioning regarding payer relationships, reimbursement dynamics, and digital care delivery economics.
The investment narrative for ISRG currently hinges on management's ability to convert strong usage of its da Vinci and Ion robotic platforms into sustained growth in instruments, accessories, and digital revenue. Analysts project US$15.5 billion in revenue and US$4.8 billion in earnings by 2029, assuming an annual revenue growth rate of 11.9% and expanding profit margins from 28.4% to 30.7%.
Valuation metrics indicate that ISRG trades at a significant premium compared to the wider US medical equipment sector, with a trailing P/E above 50x and an implied forward multiple of roughly 43.5x against consensus 2029 earnings. This high valuation leaves little room for operational missteps or disappointments in procedure growth, pricing power, or hospital capital budget constraints.
The stock faces near-term risks from competitive pressure in soft tissue robotics and potential policy headwinds that could impact reimbursement rates. While the board expansion addresses long-term economic concerns, the immediate catalyst remains execution on system placements and cost-per-case initiatives to justify the current premium multiple.
π ISRG appoints former Amazon/Humana exec Aaron Martin to board effective Jan 1, 2027.
π Analysts forecast US$15.5B revenue and US$4.8B earnings for ISRG by 2029.
π° Profit margins expected to expand from 28.4% today to 30.7% by 2029.
π ISRG trades at >50x trailing P/E, significantly above the 24.8x US medical equipment sector average.
β οΈ Bearish models project US$4.2B 2029 earnings due to procedure growth and pricing sensitivity.
π Intuitive Surgical appointed Aaron Martin, a former Amazon healthcare executive and Humana President of Insurance, to its board effective January 1, 2027.
π Analysts forecast US$15.5 billion in revenue and US$4.8 billion in earnings for ISRG by 2029, implying roughly US$1.7 billion in additional annual profit.
π° The company is expected to expand profit margins from 28.4% today to 30.7% by 2029 as it squeezes more value from each dollar of sales.
π ISRG trades at a trailing P/E above 50x, significantly higher than the 24.8x multiple cited for the wider US medical equipment group.
β οΈ Bearish analysts model 2029 earnings closer to US$4.2 billion, highlighting sensitivity to procedure growth and pricing pressures.
π¬ The near-term story depends on converting da Vinci and Ion usage into instrument and accessory revenue while managing hospital budget constraints.
π₯ New robotic competitors and remanufactured instruments are pressuring pricing, requiring hospitals to see continued clinical and economic value.
π The implied forward P/E of 43.5x is slightly below the current 44.3x multiple but remains well above sector peers.
π‘οΈ Operational catalysts like da Vinci procedure growth and Ion adoption are critical to sustaining the high valuation multiple.
Bullish Signals
Board added Aaron Martin for payer/telehealth expertise.
Analysts project 11.9% annual revenue growth through 2029.
Risk Factors
Trades at >50x P/E with margins under scrutiny.
Bearish models project 2029 revenue as low as $14.9B.
Bullish Signals
Intuitive Surgical expanded its board with Aaron Martin, bringing deep payer and telehealth experience to address long-term reimbursement and digital care economics.
Analysts project robust revenue growth of 11.9% annually through 2029, driven by da Vinci procedure volumes, Ion expansion, and digital services adoption.
Risk Factors
The stock trades at a premium P/E above 50x with margins under scrutiny, leaving little room for operational missteps or disappointments in system placements.
Bearish analysts warn that the company may struggle to offset pricing and policy pressure, modeling 2029 revenue as low as US$14.9 billion.
Intuitive Surgical, Inc. (NASDAQ:ISRG) director Craig Barratt sold 1,150 shares of company stock on November 4th for a total transaction value of $529,000 at an average price of $460.00 per share. This sale represented a 50% decrease in his direct ownership, though the transaction was executed under a pre-arranged Rule 10b5-1 trading plan, indicating it was not a spontaneous decision based on non-public information.
The medical equipment provider recently reported strong financial results for the quarter ended October 20th, with earnings per share of $3.00 beating analyst consensus estimates of $2.65. Revenue reached $3.05 billion, surpassing expectations of $2.91 billion, driven by a 21.7% year-over-year increase. The company maintained healthy profitability with a net margin of 25.54% and a return on equity of 18.17%, while trading at a market capitalization of $162.41 billion.
Wall Street sentiment remains mixed but generally positive, with a consensus rating of 'Moderate Buy' and a target price of $493.54. While HSBC lowered its rating to 'Hold', other major firms like Sanford C. Bernstein, BMO Capital Markets, and Wall Street Zen maintain 'Outperform' or 'Buy' ratings. Institutional ownership is significant at 83.64%, with notable increases in stakes from hedge funds such as QRG Capital Management and NewEdge Advisors during the second quarter.
π Director Craig Barratt sold 1,150 shares for $529,000 under a Rule 10b5-1 plan.
π° ISRG beat Q3 earnings estimates with $3.00 per share versus $2.65 consensus.
π Revenue reached $3.05 billion, exceeding expectations of $2.91 billion by $0.14B.
Intuitive Surgical (ISRG) shares have rallied 30.9% over the past three months, driven by a recent 9.4% jump despite the broader S&P 500 remaining flat. However, the stock remains 18.7% below its January high and trades at a premium valuation of 56.9 times trailing earnings, significantly higher than the S&P 500's multiple of 22.8x.
Financial analysis indicates that much of this recent price appreciation has already been priced into the stock's earnings multiple, which rose from 48.0x at the end of September to current levels. The company reported a third-quarter operating margin of 32.3%, though net margins were impacted by a $450 million litigation settlement with U.S. customers, resulting in a net margin of 17.1% compared to 28.3% in the prior quarter.
Analysts forecast Intuitive Surgical needs approximately 15% revenue growth in the fourth quarter of 2026 to meet expectations, projecting $3.3 billion against $2.87 billion a year earlier. Management has narrowed its guidance for da Vinci procedure growth to 14-15% for 2026 and anticipates lower prices in China will reduce revenue per procedure by 3-5% once fully implemented.
The stock faces volatility ahead of the fourth-quarter 2026 earnings report expected in January 2027, where management plans to provide operating expense guidance. Historical data shows significant price swings following reports, with the stock falling 26% during a previous tariff shock, suggesting investors must weigh the risk of missing out on upside if results beat forecasts against the potential for downside if they miss.
π ISRG shares gained 30.9% in three months, including a 9.4% jump on Nov 4.
π° Stock trades at 56.9x earnings with 84% of Q3 revenue being recurring.
βοΈ Q3 net margin dropped to 17.1% due to a $450 million litigation settlement.
π¬ da Vinci procedure growth guidance narrowed to 14-15% for 2026.
π Intuitive Surgical shares have gained 30.9% in three months, including a 9.4% jump on November 4, though they remain 18.7% below their January high.
π° The stock trades at 56.9 times trailing earnings, compared to 22.8x for the S&P 500, with management noting 84% of third-quarter revenue is recurring.
βοΈ Third-quarter net margin was 17.1%, down from 28.3% in the second quarter, due to a $450 million litigation settlement with U.S. customers.
π Analysts expect Intuitive Surgical to grow revenue about 15% in the fourth quarter of 2026 to meet expectations of $3.3 billion.
π¬ Management narrowed da Vinci procedure growth guidance to 14-15% for 2026 after previously projecting 13.5-15.5%.
π¨π³ Lower prices in China and wider pricing actions on instruments are expected to lower revenue per procedure by 3-5% once fully implemented.
π Intuitive Surgical is scheduled to report fourth-quarter 2026 results in January 2027, alongside updated long-term opportunity estimates.
π The stock fell 12.2% following the July 2026 report and rose 19.1% after the October 2025 report, highlighting earnings-driven volatility.
π‘οΈ During the 2025 tariff shock, Intuitive Surgical declined 26.0%, outperforming the S&P 500's 19.0% decline in terms of downside protection relative to its own history.
Risk Factors
Net margin depressed to 17.1% due to $450M litigation settlement.
Bullish Signals
The company maintains a high recurring revenue base, with management stating that 84% of third-quarter revenue was recurring.
Intuitive Surgical has demonstrated strong historical growth, with revenue increasing between 18.5% and 23.0% in each of the past four quarters.
The stock showed resilience during market stress, falling only 26.0% during the 2025 tariff shock compared to a broader market decline.
Risk Factors
Third-quarter net margin was significantly depressed at 17.1% due to a $450 million litigation settlement with U.S. customers.
Management expects lower prices in China and wider pricing actions on instruments will reduce da Vinci instrument and accessory revenue per procedure by about 3% to 5%.
Analysts anticipate a slowdown in growth, expecting only about 15% revenue growth in the fourth quarter of 2026 compared to higher single-digit or double-digit growth previously.
The stock remains 18.7% below its January high, suggesting recent gains may have already priced in much of the positive momentum.
Intuitive Surgical reported strong third-quarter financial results driven by significant growth in its core surgical platforms, though reported earnings were impacted by a proposed antitrust settlement. The company posted revenue of USD 3.05 billion, representing a 22 percent year-over-year increase, with worldwide procedures on the da Vinci and Ion systems rising approximately 15 percent.
Operational metrics highlighted robust demand for Intuitive Surgical's robotic surgery solutions, with 546 da Vinci surgical systems placed during the quarter compared to 427 in the prior year. The installed base expanded by 12 percent to 12,094 da Vinci systems and grew 21 percent to 1,152 Ion systems, indicating a healthy recurring revenue environment supported by instrument sales.
Despite a USD 450 million pre-tax charge related to the antitrust litigation settlement, which did not include an admission of liability, Intuitive Surgical's non-GAAP net income rose to USD 3.00 per diluted share. Management maintains positive guidance for 2026, projecting da Vinci procedure growth near the midpoint of its 14 to 15 percent range and gross margins between 68.7 and 69.3 percent.
Intuitive Surgical stock traded at EUR 425.08 on Lang & Schwarz following the earnings release. The company's ability to balance organic procedure expansion with the financial weight of legal settlements remains a key factor for investors evaluating its long-term trajectory in the medical technology sector.
π Q3 revenue surged 22% to USD 3.05 billion driven by procedure volume growth.
π¬ Worldwide procedures rose 15%, with Ion platform specifically up 31%.
π° Instruments and accessories revenue increased 18% to USD 1.80 billion.
βοΈ GAAP earnings fell due to a USD 450 million antitrust settlement charge.
π Non-GAAP net income per share grew to USD 3.00 excluding the charge.
π Intuitive Surgical revenue surged 22 percent year-over-year to USD 3.05 billion in the third quarter.
π¬ Worldwide procedures on da Vinci and Ion platforms increased approximately 15 percent, with Ion specifically up 31 percent.
π₯ The company placed 546 da Vinci surgical systems in the quarter, including 315 of the newer da Vinci 5 models.
π The installed base grew to 12,094 da Vinci systems and 1,152 Ion systems, reflecting strong market penetration.
π° Instruments and accessories revenue reached USD 1.80 billion, an 18 percent increase driven by procedure volume.
βοΈ A proposed antitrust settlement resulted in a USD 450 million pre-tax charge against reported GAAP earnings.
π GAAP net income per diluted share fell to USD 1.49 due to the legal charge, dropping from USD 1.95 a year ago.
π Non-GAAP net income per diluted share increased to USD 3.00, excluding the one-time settlement impact.
π― Management forecasts da Vinci procedure growth near the midpoint of its 14 to 15 percent range for 2026.
πΉ Projected non-GAAP gross margins are expected to remain strong between 68.7 and 69.3 percent in 2026.
π The antitrust agreement includes injunctive relief but explicitly does not admit liability or wrongdoing by the company.
π Intuitive Surgical stock traded at EUR 425.08 on Lang & Schwarz following the earnings announcement.
Intuitive Surgical reported robust third-quarter financial performance for the period ended September 30, 2026, driven by significant growth in its core robotic surgery business. Total revenue surged 22% year-over-year to reach $3.05 billion, fueled by a 15% increase in worldwide procedures across both da Vinci and Ion platforms. System placements also accelerated, with the company installing 546 da Vinci systems compared to 427 in the prior-year quarter.
Despite strong operational metrics, reported earnings were impacted by a substantial proposed antitrust settlement related to class-action litigation. This event triggered a $450 million pretax charge that reduced GAAP net income to $523 million, or $1.49 per diluted share, down from $704 million in the previous year. However, on a non-GAAP basis which excludes this one-time charge, net income rose to $1.05 billion and adjusted diluted earnings increased to $3.00 per share.
Management maintains optimistic guidance for the remainder of 2026, projecting worldwide da Vinci procedure growth near the midpoint of its 14% to 15% target range. The company also forecasts a non-GAAP gross margin between 68.7% and 69.3%, with operating expenses expected to grow 11% to 13%. These figures assume current tariff conditions remain stable through year-end, highlighting the company's continued focus on profitability despite legal headwinds.
Intuitive Surgical stock traded at 393.63 euros on November 3, 2026, reflecting a 1.10% gain following the report release. The divergence between strong underlying procedure volume growth and the drag from the legal settlement illustrates the company's ability to expand its market footprint while navigating significant regulatory challenges.
π Revenue surged 22% YoY to $3.05B driven by 15% procedure growth.
π§ da Vinci system placements accelerated to 546 units including 315 new da Vinci 5s.
βοΈ Antitrust settlement caused $450M charge reducing GAAP net income to $523M.
π― Management forecasts worldwide da Vinci procedure growth near 14% to 15% target for 2026.
π Intuitive Surgical revenue jumped 22% year-over-year to $3.05 billion, driven by a 15% increase in worldwide procedures across da Vinci and Ion platforms.
π§ System placements accelerated significantly with 546 da Vinci systems installed in the quarter versus 427 last year, including 315 new da Vinci 5 units.
βοΈ A proposed antitrust settlement resulted in a $450 million pretax charge that reduced GAAP net income to $523 million or $1.49 per diluted share.
π° On a non-GAAP basis excluding the legal charge, net income rose to $1.05 billion and adjusted diluted earnings reached $3.00 per share.
π― Management forecasts worldwide da Vinci procedure growth near the midpoint of its 14% to 15% target range for the remainder of 2026.
πΉ The company projects a non-GAAP gross margin between 68.7% and 69.3% with operating expenses growing 11% to 13% under current tariff assumptions.
π GAAP earnings per share declined from $1.95 in the prior-year quarter due to the one-time legal charge impacting reported profitability.
π Ion platform procedures advanced by 31%, demonstrating strong adoption of the company's newer robotic technology alongside established da Vinci systems.
πΆ Intuitive Surgical stock price rose 1.10% to 393.63 euros following the release of the quarterly earnings report and guidance update.
π‘οΈ The antitrust agreement includes injunctive relief without an admission of liability, subject to preliminary and final court approval.
Bullish Signals
Revenue rose 22% to $3.05B driven by procedure volume.
Risk Factors
Antitrust charge reduced GAAP net income to $523 million.
Intuitive Surgical achieved a 22% year-over-year revenue increase to $3.05 billion, demonstrating strong top-line growth driven by procedure volume.
Worldwide procedures grew approximately 15%, with da Vinci procedures rising 14% and Ion procedures surging 31%, indicating broad platform adoption.
The company placed 546 da Vinci systems in the quarter, a significant increase from 427 last year, including 315 new da Vinci 5 units.
Non-GAAP net income increased to $1.05 billion and adjusted diluted earnings rose to $3.00 per share, excluding the one-time legal charge.
Management expects worldwide da Vinci procedure growth near the midpoint of its 14% to 15% target range for the rest of 2026.
Instruments and accessories revenue grew 18% to $1.80 billion, showing strong recurring revenue potential from consumables.
Risk Factors
A proposed antitrust settlement triggered a $450 million pretax charge that significantly reduced GAAP net income to $523 million.
GAAP earnings per share fell to $1.49 from $1.95 in the prior-year quarter due to the impact of the legal settlement charge.
The antitrust agreement remains subject to preliminary and final court approval, introducing regulatory uncertainty regarding the timing of the charge recognition.
Intuitive Surgical (ISRG) faces a potential headwind as management plans to reduce pricing for da Vinci instruments and accessories, starting with a significant policy change in China later this year. The company expects these adjustments to lower revenue per procedure by approximately 3% to 5% once fully implemented across all markets. This strategic move aims to address customer value regarding reliability and economics, particularly in high-volume operations like hernia repair, while rolling out longer-life instruments country by country from the first half of 2027.
Despite the anticipated price cuts, Intuitive Surgical believes that procedural volume growth will more than offset the revenue impact. Management narrowed its 2026 forecast for da Vinci procedure growth to a range of 14% to 15%, driven by strong international expansion and a shift toward newer systems like da Vinci 5 and SP. Consequently, the company raised its adjusted gross margin guidance for 2026 to between 68.7% and 69.3%, citing lower product costs that helped lift margins in fiscal Q3 2026.
Key risks remain centered on U.S. demand dynamics and valuation concerns. While international procedures grew at 20% compared to a 10% increase in the U.S., Intuitive is monitoring challenges related to ACA enrollment and Medicaid eligibility changes. Investors are also weighing the stock's high valuation, trading at 51 times earnings, against its recent performance in market sell-offs, with the upcoming January 2027 earnings report expected to provide critical updates on operating expenses and long-term surgical opportunities.
π Intuitive Surgical cuts da Vinci pricing by 3% to 5% starting in China.
π Procedural volume growth expected to exceed price reductions globally.
π° Adjusted gross margin guidance raised to 68.7%β69.3% for 2026.
β οΈ U.S. demand remains a key uncertainty with only 10% Q3 growth.
π SP procedures surged 55% as da Vinci 5 and Ion mix expands.
π Intuitive Surgical plans to reduce da Vinci instrument pricing by 3% to 5% once fully implemented, starting with a billing-code policy change in China.
π The company expects procedural volume growth to exceed the price cuts, narrowing the gap between procedure count and revenue per unit.
π° Management raised its 2026 adjusted gross margin guidance to 68.7%β69.3%, driven by lower product costs and a shift toward da Vinci 5 systems.
πΊπΈ U.S. demand remains a key uncertainty, with procedures growing at 10% in Q3 2026 versus 20% growth outside the U.S.
π SP procedures surged 55% in fiscal Q3 2026 as da Vinci 5 and Ion systems become larger shares of the business mix.
β οΈ The stock trades at a premium 51x earnings, having underperformed the S&P 500 during recent market shocks like inflation and tariff events.
π Management will provide updated operating expense guidance and long-term opportunity estimates in the January 2027 earnings report.
Bullish Signals
Raised 2026 gross margin guidance to 68.7%-69.3% due to lower costs.
SP procedures grew 55% in Q3 2026, boosting revenue per procedure.
Instrument sales grew 18%, outpacing total procedure growth.
Risk Factors
China pricing cuts lower da Vinci revenue per procedure by 3-5%.
U.S. da Vinci procedures grew only 10% in Q3 2026.
Bullish Signals
Intuitive Surgical raised its 2026 adjusted gross margin guidance to a range of 68.7% to 69.3%, driven by lower product costs that boosted margins in fiscal Q3 2026.
SP procedures grew 55% in fiscal Q3 2026, indicating strong adoption of newer da Vinci 5 and SP systems which are expected to add to revenue per procedure.
Instrument and accessory sales grew 18% in the quarter, outpacing the 15% growth in total procedures, demonstrating strong demand for consumables.
Risk Factors
Management expects pricing changes and a specific cut in China to lower da Vinci instrument revenue per procedure by approximately 3% to 5% once fully implemented.
U.S. da Vinci procedures grew only 10% in fiscal Q3 2026, significantly trailing the 20% growth seen outside the U.S., raising concerns about domestic demand saturation or regulatory headwinds.
Shares of Intuitive Surgical (NASDAQ: ISRG) declined following its earnings report on October 20, despite the company reporting a significant 22% revenue jump. The article argues that investors are overlooking the fact that sales of the da Vinci surgical robot systems are not the primary driver of the company's top line. Instead, recurring revenue from instruments, accessories, and services constitutes the majority of ISRG's business model.
The report highlights that while competition from major medical device makers like Medtronic and Johnson & Johnson is intensifying, Intuitive Surgical continues to grow its installed base. In the third quarter of 2026, the company sold more da Vinci systems than in the same period of 2025. Furthermore, the number of procedures performed using da Vinci systems increased by 15% year over year, outpacing the 12% growth in installed systems, indicating strong underlying demand.
Intuitive Surgical maintains a robust financial foundation with an installed base exceeding 12,000 systems, which generates annuity-like cash flows from parts and services. The article suggests that despite new entrants in the market, there is ample room for global growth as robotic surgery adoption expands. Although ISRG was not included in The Motley Fool's recent top 10 stock list, the analysis emphasizes its strong recurring income stream and non-saturation of the surgical robotics market.
Intuitive Surgical reported robust third-quarter financial performance driven by significant growth in both system placements and procedure volumes. Revenue for the quarter ended September 30 reached $3.05 billion, representing a 22% year-over-year increase from the prior period. This growth was fueled by a 14% rise in da Vinci procedures and a substantial 31% increase in Ion procedures, alongside an 18% surge in instruments and accessories revenue.
Despite strong operational metrics, GAAP net income declined to $523 million due to a $450 million pretax charge associated with a proposed antitrust litigation settlement. On a non-GAAP basis, however, the company demonstrated underlying profitability growth, with net income rising to $1.05 billion. The installed base expanded significantly, reaching 12,094 da Vinci systems and 1,152 Ion systems, reflecting continued market adoption.
Management provided forward-looking guidance expecting worldwide da Vinci procedure growth between 14% and 15% for the full year 2026. The company also forecasts a non-GAAP gross margin of 68.7% to 69.3% and operating expense growth of 11% to 13%, contingent on current tariff conditions remaining in force through year-end. CEO Dave Rosa highlighted high daily procedure volumes, averaging over 10,000 per day during the quarter.
π ISRG revenue surged 22% to $3.05B driven by da Vinci and Ion systems.
π§ Company placed 546 da Vinci units, including 315 of the newer da Vinci 5 model.
βοΈ GAAP earnings impacted by $450M pretax charge for proposed antitrust litigation settlement.
π° Instruments revenue jumped 18% to $1.80B as customers utilized more consumables.
π₯ Installed base expanded to 12,094 da Vinci and 1,152 Ion systems by September end.
π Intuitive Surgical revenue surged 22% to $3.05 billion in Q3, driven by strong performance across da Vinci and Ion systems.
π§ The company placed 546 da Vinci systems in the quarter, including 315 units of the newer da Vinci 5 model.
βοΈ GAAP earnings were impacted by a $450 million pretax charge related to a proposed antitrust litigation settlement.
π Non-GAAP net income increased to $1.05 billion, reflecting underlying business growth despite the legal expense.
π Worldwide da Vinci procedure volume is expected to grow 14% to 15% in 2026, with performance near the midpoint.
π° Instruments and accessories revenue jumped 18% to $1.80 billion as customers utilized more consumables.
π₯ The installed base expanded to 12,094 da Vinci systems and 1,152 Ion systems by the end of September.
π Operating expenses are forecasted to grow 11% to 13% for the full year under current tariff conditions.
π¨βπΌ CEO Dave Rosa noted customers performed over 10,000 procedures per day on average during the third quarter.
π The proposed antitrust settlement requires preliminary and final court approval before becoming effective.
Bullish Signals
Revenue grew 22% YoY to $3.05B.
Non-GAAP net income rose to $1.05B.
Placed 546 da Vinci systems in Q3.
Ion procedures climbed 31% year-over-year.
Instruments revenue increased 18% to $1.80B.
Risk Factors
GAAP net income fell $523M due to $450M antitrust charge.
Bullish Signals
Revenue grew 22% year-over-year to $3.05 billion, demonstrating strong top-line momentum driven by system adoption and procedure volume.
Non-GAAP net income rose to $1.05 billion, indicating robust underlying profitability despite the one-time legal charge.
The company placed 546 da Vinci systems in Q3, including a significant number of the newer da Vinci 5 models, expanding its installed base.
Ion procedures climbed 31% year-over-year, highlighting successful diversification and growth in the company's second robotic platform.
Instruments and accessories revenue increased 18% to $1.80 billion, reflecting high utilization rates and recurring revenue streams.
Management expects worldwide da Vinci procedure growth of 14% to 15% for 2026, with performance anticipated near the midpoint of that range.
Risk Factors
GAAP net income fell to $523 million due to a $450 million pretax charge tied to a proposed antitrust litigation settlement.
The proposed antitrust settlement includes injunctive relief and payments but remains subject to preliminary and final court approval.
Operating expenses are forecasted to grow 11% to 13% for the full year, which may compress margins if procedure growth does not keep pace.
Intuitive Surgical (ISRG) is expanding hospital adoption of its da Vinci robotic systems through leasing, with operating leases accounting for 54% of second-quarter placements compared to 49% a year prior. This strategy lowers upfront costs for hospitals but requires shareholders to fund equipment before collecting lifetime returns, making the business more capital intensive while sustaining growth.
The company trades at a premium valuation of 33x forward P/E versus Stryker's 16x, justified by analysts expecting 21% non-GAAP adjusted EPS growth in 2026 compared to Stryker's 10%. However, the high multiple demands sustained procedure volumes and cash returns to cover equipment costs, as slower expansion and continued investment requirements support a lower valuation than previous levels.
Financial performance remains robust with second-quarter GAAP EPS of $2.29 and adjusted EPS of $2.80, supported by $1.97 billion in first-half operating cash flow. While usage-based arrangements match hospital payments to procedures, industry conditions like expired health-insurance subsidies have slowed U.S. procedure growth, creating risks for instrument demand and equipment utilization.
π Operating lease revenue surged 22% to $262 million in Q2.
π Worldwide da Vinci procedures rose 15% with 3% utilization gain.
π° First-half operating cash flow reached $1.97 billion after capex.
π Trades at demanding 33x forward P/E versus peer Stryker's 16x.
β οΈ U.S. procedure growth slowed to 12% due to subsidy expiry.
π Operating lease revenue increased 22% to $262 million in the second quarter, outpacing systems revenue growth of 19%.
π Worldwide da Vinci procedures rose 15% while utilization increased 3%, demonstrating that busier systems generate additional sales beyond lease payments.
π° Intuitive Surgical generated $1.97 billion of first-half operating cash flow, leaving approximately $1.76 billion after property and equipment purchases.
π The company trades at a demanding 33x forward P/E valuation compared to 16x for peer Stryker Corporation.
β οΈ U.S. procedure growth eased to 12% versus 20% outside the United States, linked by management to expired enhanced health-insurance subsidies.
π Analysts expect calendar-2026 non-GAAP adjusted EPS growth of approximately 21% for Intuitive Surgical versus 10% for Stryker.
Bullish Signals
Operating lease revenue grew 22% to $262 million in Q2.
Risk Factors
Trades at 33x forward P/E vs. 16x peer Stryker.
U.S. procedure growth eased to 12% from 20%.
Leasing model ties up investment longer than sales.
Forward P/E compressed from 59x to 38x.
Bullish Signals
Operating lease revenue increased 22% to $262 million in the second quarter, ahead of 19% systems revenue growth.
Worldwide da Vinci procedures rose 15% while utilization increased 3%, demonstrating that busier systems generate additional sales beyond lease payments.
Instruments and accessories revenue rose 18%, showing how usage-based arrangements drive incremental profits.
The company generated $1.97 billion of first-half operating cash flow, leaving approximately $1.76 billion after property and equipment purchases.
Analysts expect calendar-2026 non-GAAP adjusted EPS growth of approximately 21%, significantly outpacing peer Stryker's expected 10% growth.
Risk Factors
The company trades at a demanding 33x forward P/E valuation compared to 16x for peer Stryker Corporation, requiring sustained performance to justify the premium.
U.S. procedure growth eased to 12% versus 20% outside the United States, linked by management to expired enhanced health-insurance subsidies.
Leasing makes the business more capital intensive as shareholders fund equipment before collecting lifetime returns, tying up investment longer than outright sales.
Slower expansion and continuing investment requirements support a lower valuation than previous levels, with forward P/E compressing from 59x to 38x.
Company updateEarnings reportAI-generated analysis
Intuitive Surgical (ISRG) faces a divergence between its robust business performance and its stock market trajectory, having declined nearly 24% in 2026 despite double-digit growth in procedures, revenue, and installed base. The company's forward P/E ratio stands at approximately 36x, reflecting a significant premium over peers like Medtronic that investors are paying for its dominant position in robotic-assisted surgery.
In the second quarter of 2026, ISRG reported revenue growth of 19% to $2.89 billion, driven by a 16% increase in worldwide da Vinci and Ion procedures. The installed base expanded significantly with 11,710 da Vinci systems and 1,096 Ion systems, while the company placed 468 new da Vinci systems, including a notable uptake of the newer da Vinci 5 platform.
Management expects procedure growth to continue at approximately 13.5% to 15.5% for the full year 2026. However, the high valuation leaves little room for error; while GAAP net income rose to $818 million, the company anticipates non-GAAP operating expenses will increase by 11% to 13% in 2026, and tariffs are expected to reduce gross margins by about one percentage point.
π ISRG shares down 24% YTD despite strong fundamentals and outperforming peers.
π° Trades at 36.36x forward P/E, a premium over traditional medical device rivals.
π Q2 revenue surged 19% to $2.89B driven by da Vinci and Ion growth.
β οΈ Tariffs expected to reduce gross margins by approximately one percentage point.
ποΈ High valuation requires continued exceptional execution to justify the premium multiple.
π ISRG shares have declined nearly 24% since the start of 2026, underperforming the S&P 500 despite strong underlying business fundamentals.
π° The company trades at a forward P/E of approximately 36.36x, representing a substantial premium over traditional medical device peers like Medtronic.
π Q2 2026 revenue surged 19% year-over-year to $2.89 billion, driven by double-digit growth in both da Vinci and Ion procedures.
π§ The installed base of surgical systems expanded significantly, with da Vinci units rising 12% to 11,710 systems and Ion units increasing 21% to 1,096 systems.
π Placement activity accelerated in Q2 with 468 da Vinci systems placed, including a strong push for the newer da Vinci 5 platform.
π Management forecasts worldwide da Vinci procedure growth between 13.5% and 15.5% for the remainder of 2026.
πΈ GAAP net income increased to $818 million in Q2, though non-GAAP operating expenses are projected to rise 11-13% in 2026.
β οΈ Tariffs are expected to negatively impact gross margins by approximately one percentage point in the coming year.
ποΈ The high valuation implies that continued exceptional execution is required to justify the premium multiple over time.
Bullish Signals
Procedures, revenue, and installed base grew double-digits in Q2 2026.
Risk Factors
Stock down 24% since start of 2026.
Tariffs cut gross margins by ~1%.
Forward P/E of 36x exceeds peers.
Bullish Signals
Intuitive Surgical achieved double-digit growth in procedures, revenue, and installed base during Q2 2026, demonstrating resilient business performance.
Revenue increased 19% year-over-year to $2.89 billion in the second quarter of 2026, validating demand for its robotic surgery platforms.
The company successfully placed 468 da Vinci systems in Q2, indicating strong market penetration and adoption of newer technology like the da Vinci 5.
GAAP net income rose to $818 million in Q2 2026, reflecting strong profitability despite a challenging macro environment.
Risk Factors
The stock has underperformed the broader market with a nearly 24% decline since the start of 2026, putting its premium valuation under scrutiny.
Tariffs are projected to reduce gross margins by approximately one percentage point, adding a specific headwind to profitability.
The forward P/E of roughly 36x is significantly higher than peers like Medtronic, leaving little room for disappointment in future earnings growth.
Intuitive Surgical (ISRG) currently trades at a forward multiple of approximately 40x adjusted earnings over the last twelve months, reflecting investor expectations for significant future growth. Analyst consensus forecasts project net income reaching $3.99 billion in fiscal 2026 and rising to $4.55 billion by fiscal 2027. Under these projections, the company's current market valuation would correspond to a multiple of roughly 39.5x for fiscal 2026 earnings and drop to 34.7x for fiscal 2027, suggesting the stock is priced based on future profitability rather than just past performance.
Revenue growth is expected to moderate from the double-digit pace seen recently to approximately 12.1% in fiscal 2027, while management anticipates worldwide da Vinci procedures will increase by 14% to 15% in fiscal 2026. The consensus forecast also assumes a tightening of net margins, projecting a rise from 31.5% in fiscal 2025 to 34.1% in fiscal 2027. This margin expansion is driven by the expectation that the company will retain a higher percentage of sales as profit compared to the roughly 34% retention rate observed over the last twelve months.
However, potential headwinds could cause Intuitive Surgical to miss these optimistic forecasts, primarily through pricing pressures and increased operational costs. Management indicated on its Q3 2026 call that price reductions in China and the rollout of longer-life instruments will lower revenue per procedure by 3% to 5%. Additionally, the company faces potential higher input costs related to freight and semiconductor memory, while operating expense guidance for fiscal 2027 is not yet available and will be released in January 2027.
If Intuitive Surgical fails to deliver on these margin expansion targets due to the cited pricing cuts or cost increases, the stock could face downside risk as it remains priced for profit levels the company has not yet achieved. Investors are advised to monitor management's upcoming operating expense guidance in January 2027 to assess whether the consensus margin assumptions remain realistic given the anticipated headwinds in instrument pricing and input costs.
π ISRG trades at 40x forward earnings with $3.99B net income expected in FY2026.
π Revenue growth slows to 12.1% in FY2027 as China pricing cuts lower revenue per procedure by 3-5%.
π° Net margins expand from 31.5% in FY2025 to 34.1% in FY2027 despite higher input costs.
β οΈ Higher freight and semiconductor memory costs may pressure operating expense guidance for FY2027.
π‘οΈ Current valuation risks margin shortfall if pricing cuts or cost increases materialize before profit realization.
π Intuitive Surgical trades at a forward multiple of roughly 40x adjusted earnings, implying significant growth expectations for future profitability.
π Analysts forecast net income to reach $3.99 billion in fiscal 2026 and $4.55 billion in fiscal 2027.
π Revenue growth is expected to slow to 12.1% in fiscal 2027 compared to the 20.5% reported over the last twelve months.
π Management expects worldwide da Vinci procedures to grow between 14% and 15% in fiscal 2026.
π° Net margins are forecasted to expand from 31.5% in fiscal 2025 to 34.1% in fiscal 2027.
π Instrument pricing actions, including a price reduction in China, are expected to lower revenue per procedure by 3% to 5%.
β οΈ Management anticipates higher input costs in areas such as freight and semiconductor memory for the upcoming fiscal year.
ποΈ Operating expense guidance for fiscal 2027 is pending and will be released in January 2027.
π‘οΈ The stock is currently priced based on future profit levels that Intuitive Surgical has not yet realized.
βοΈ A shortfall in margin expansion due to pricing cuts or cost increases would make the current valuation a riskier bet.
Bullish Signals
Net income projected at $3.99B in FY2026 and $4.55B in FY2027.
Worldwide da Vinci procedures expected to grow 14-15% in FY2026.
Net margin forecast expands from 31.5% in FY2025 to 34.1% in FY2027.
Risk Factors
China price cuts may lower da Vinci revenue per procedure by 3% to 5%.
Higher input costs like freight could compress profit margins.
Revenue and margin could miss expectations if forecasts ignore pricing cuts.
Bullish Signals
Analyst consensus forecasts project net income growth to $3.99 billion in fiscal 2026 and $4.55 billion in fiscal 2027.
Management expects worldwide da Vinci procedures to grow by 14% to 15% in fiscal 2026.
The consensus forecast assumes a net margin expansion from 31.5% in fiscal 2025 to 34.1% in fiscal 2027.
Risk Factors
Management indicated that pricing actions and a price reduction in China will lower da Vinci instrument and accessory revenue per procedure by about 3% to 5% once fully implemented.
The company expects higher input costs in areas like freight and semiconductor memory, which could compress profit margins.
Operating expense guidance for fiscal 2027 is not yet available, creating uncertainty around the company's cost management strategy.
If consensus forecasts do not fully account for pricing cuts and cost increases, both revenue and margin could come in below expectations.
Intuitive Surgical (ISRG) shares fell 7.5% in pre-market trading following its third-quarter 2026 earnings report, despite adjusted EPS of $3.00 and revenue of $3.05 billion both beating analyst estimates. The stock decline was primarily driven by a $450 million pre-tax charge related to the settlement of the da Vinci Surgical Robot Antitrust Litigation, which reduced GAAP net income to $1.49 per share compared to $1.95 in the prior-year period.
Management confirmed plans to reduce pricing for certain surgical instruments and accessories by approximately 3% to 5% on a constant-mix basis once fully implemented. This strategic adjustment is expected to lower revenue per procedure, prompting investor scrutiny regarding its impact on the company's recurring revenue stream from installed robotic systems. The move aims to potentially stimulate demand, though the net effect on overall growth remains dependent on future procedure volumes and operating costs.
Operational performance showed a divergence between domestic and international markets, with US da Vinci procedures rising 10% year-over-year while international volumes surged 20%. Analysts from major banks including JPMorgan, Raymond James, and Barclays maintained positive ratings but adjusted price targets to reflect the pricing changes and legal settlement. The market is closely watching whether higher procedure volumes, particularly in international markets, can offset the revenue headwinds from lower instrument pricing as the company heads into 2027.
βοΈ GAAP net income dropped to $1.49/share due to a $450M antitrust charge.
π Management plans 3-5% price cuts on surgical instruments and accessories.
π International da Vinci procedure volumes rose 20%, outpacing US growth of 10%.
π Adjusted EPS hit $3.00 vs $2.65 estimate; revenue reached $3.05B.
π ISRG shares declined 7.5% to $404.99 in pre-market trading following Q3 2026 earnings despite beating adjusted EPS and revenue estimates.
βοΈ The company recorded a $450 million pre-tax charge for the settlement of the da Vinci Surgical Robot Antitrust Litigation, reducing GAAP net income to $1.49 per share.
π Management plans to reduce pricing on surgical instruments and accessories by 3% to 5%, which is expected to lower revenue per procedure once fully implemented.
π International da Vinci procedure volumes increased by 20% year-over-year, outpacing the 10% growth seen in the US market.
π Analysts maintained positive ratings with JPMorgan raising its price target to $475 and Barclays increasing it to $500 despite the pricing adjustments.
π Investors are assessing whether higher procedure volumes can offset the revenue impact of the planned pricing reductions on recurring revenue streams.
π Adjusted EPS of $3.00 exceeded the consensus estimate of $2.65, while total revenue reached $3.05 billion against expectations of $2.91 billion.
Bullish Signals
Earnings of $3.00 beat consensus of $2.65.
Risk Factors
$450M antitrust charge significantly reduced GAAP net income.
US procedure growth slowed to 10%, a recent low.
Bullish Signals
Intuitive Surgical reported third-quarter non-GAAP earnings of $3.00 per share, surpassing the analyst consensus estimate of $2.65.
Revenue reached $3.05 billion, exceeding market expectations of $2.91 billion.
International da Vinci procedure volumes increased by 20% year-over-year, indicating strong growth outside the United States.
US da Vinci procedures grew by 10% year-on-year during the third quarter.
Major investment banks maintained positive ratings with JPMorgan raising its price target to $475 and Barclays increasing it to $500.
Risk Factors
A $450 million pre-tax charge associated with the settlement of the class-action antitrust litigation reduced GAAP net income significantly.
The domestic US procedure growth rate of 10% was among the company's lowest readings in recent years, indicating slowing momentum in its largest market.
Intuitive Surgical (ISRG) is preparing to report quarterly earnings after market close on October 20, 2026. Analyst expectations for revenue growth have moderated to 15.6% year-over-year, down from 22.9% in the prior year's quarter, though forecasts remain largely unchanged heading into the release. The market is closely watching how the company's leadership in robotic surgery and its debt-free balance sheet navigate these moderating top-line expectations as the installed base and procedure mix evolve.
The investment narrative for Intuitive Surgical centers on recurring revenue streams derived from its da Vinci and Ion robotic systems. Analyst models project that revenue will grow at an 11.9% annual rate over the next three years, with profit margins expected to expand from 28.4% today to 30.7% by year three. This growth is driven by increased utilization of existing systems and a richer earnings mix as digital offerings scale alongside the growing fleet of surgical robots.
Long-term consensus forecasts suggest Intuitive Surgical could reach US$15.5 billion in revenue and US$4.8 billion in earnings by 2029, representing an increase of roughly US$1.7 billion from current levels. However, a more cautious analyst set projects lower figures of US$14.6 billion in revenue and US$4.2 billion in earnings by the same date. Key operational signals investors will scrutinize include procedure growth rates, the mix between new system placements versus leasing, and any commentary regarding competition or pricing pressure on high-margin recurring instruments.
π ISRG reports earnings after market close on October 20, 2026.
π Revenue growth expectations moderated to 15.6% year-over-year.
π° Consensus forecasts project 11.9% annual revenue growth through 2026.
π Long-term models anticipate earnings reaching US$4.8 billion by 2029.
π‘οΈ ISRG maintains a debt-free balance sheet amid competitive risks.
π Intuitive Surgical is scheduled to report earnings after market close on October 20, 2026.
π Analyst expectations for revenue growth have moderated to 15.6% year-over-year compared to 22.9% in the same quarter last year.
π° Consensus forecasts project revenue growing at 11.9% annually over the next three years with profit margins expanding from 28.4% to 30.7%.
π Long-term models anticipate earnings reaching US$4.8 billion by 2029, up from US$3.1 billion today.
β οΈ A cautious analyst set projects lower long-term earnings of US$4.2 billion by 2029 with only a small lift in profit margins.
π Key operational metrics to watch include procedure growth on da Vinci and Ion systems and the mix between new placements versus leasing.
π‘οΈ The company maintains a debt-free balance sheet while facing potential risks from competitive noise and pricing pressure on recurring revenue.
π Analyst models assume shares outstanding will edge down by about 0.34% annually over the next three years, potentially lifting earnings per share.
Bullish Signals
Debt-free balance sheet offers financial flexibility for growth investments.
Risk Factors
Revenue growth expectations moderated to 15.6% YoY.
Risks include system placement softening in China/Europe.
Early robotics competition could make short-term story fragile.
Investors watch for pricing/margin pressure on recurring revenue.
Bullish Signals
Intuitive Surgical maintains a debt-free balance sheet, providing financial flexibility to navigate market changes and invest in growth.
Analysts project profit margins will expand from 28.4% today to 30.7% by year three as the fleet grows and digital offerings scale.
The company's recurring revenue narrative is supported by increasing utilization of installed da Vinci and Ion robotic systems globally.
Consensus long-term forecasts indicate a significant earnings increase of roughly US$1.7 billion, growing from US$3.1b today to US$4.8b by 2029.
Risk Factors
Revenue growth expectations have moderated significantly to 15.6% year-over-year, down from a faster clip of 22.9% in the same quarter last year.
Risks include potential softening of system placements in pressured regions such as China or parts of Europe.
The short-term story could feel fragile if early competitive noise from new soft tissue robotics platforms picks up momentum.
Investors are watching for any visible pricing or margin pressure on high-margin recurring instruments and service revenue.
Intuitive Surgical reported strong second-quarter financial results, with revenue reaching USD 2.89 billion, representing a 19 percent year-over-year increase. GAAP net income for the quarter was USD 818.10 million, up from USD 658.00 million in the same period last year. The company's stock traded at EUR 382.35 on October 19, 2026, ahead of its scheduled third-quarter earnings report on October 20.
Operational growth was driven by a 16 percent increase in total procedures performed, with specific gains in both the da Vinci and Ion robotic systems. Da Vinci procedures grew by 15 percent while Ion procedures saw a significant 36 percent surge. The company maintains its full-year guidance for da Vinci procedure growth between 13.50 percent and 15.50 percent for 2026, indicating confidence in sustaining momentum despite recent moderation in the U.S. market.
Recurring revenue remains a critical component of Intuitive Surgical's business model, accounting for 85 percent of second-quarter sales at USD 2.47 billion. The company highlighted a meta-analysis covering 13 benign conditions that demonstrated improved patient outcomes associated with da Vinci surgery. Analysts are closely watching whether procedure growth can remain near the guidance range as international business and recurring revenue streams continue to serve as key indicators for future performance.
Intuitive Surgical operates in the healthcare medical instruments and supplies sector, listed on Nasdaq under ticker ISRG. The company's headquarters is located in Sunnyvale, where it maintains a modern campus. With the upcoming Q3 report expected to show USD 2.91 billion in consensus revenue, investors will be evaluating if the recent growth trajectory can be sustained globally.
We use cookies to run the site and, only if you allow it, for live chat, analytics, personalization and ad measurement.
We use cookies to:
Deliver and maintain our services, protect against spam, fraud and abuse
Offer a live chat with our team (Enuchat, optional)
Measure audience engagement and site statistics to understand how our services are used (Google Analytics, optional)
Remember your quiz progress and tailor the knowledge base to your skill level (optional)
Measure how our ads on Facebook and Instagram perform, including whether a visit leads to a confirmed sign-up, matched to your Facebook or Instagram account using hashed contact details you enter (Meta Pixel, optional)
Optional cookies are only set if you allow them. You can accept all, reject all or choose per category, and change your choice at any time via the "Manage Cookies" link in the footer. Google and Meta may process this data in the USA. More in our Privacy Policy.
Manage cookie preferences
Necessary cookiesAlways active
Required for the website to function. These cannot be disabled.
Cookie
Purpose
Duration
PHPSESSID
Session identifier for login, security tokens, and site functionality
Session
cookie_consent
Stores your cookie preferences
1 year
Functional cookies
Show the live chat button so you can message our team. The Enuchat chat widget stores a visitor ID in your browser and sends your chat messages to Enuchat. When this is off, the chat is not loaded.
Cookie
Purpose
Duration
enuchat_visitor_id
Keeps your chat conversation linked to this browser (Enuchat, browser storage)
Until you clear it or turn this off
Analytics cookies
Help us understand how visitors use our website with Google Analytics, provided by Google LLC. Google receives pages visited, device data and an IP address, and may process them in the USA. If you also allow marketing cookies, the Google tag can detect contact details you enter or see on our pages, such as your email address, phone number, name or address, hash them before sending and pass them to Google so it can match your visits to a Google account for measuring our ads. Hashed details are still personal data. See how Google uses information from sites that use its services.
Cookie
Purpose
Duration
_ga
Distinguishes unique visitors (Google Analytics)
2 years
_ga_*
Maintains session state (Google Analytics)
2 years
Personalization cookies
Remember your quiz progress and work out your investing level so we can recommend knowledge-base articles and the right reading depth for you. Stored only on your device.
Cookie
Purpose
Duration
bes_user_level
Your quiz-derived investing level, used to tailor content
1 year
Marketing cookies
Let Meta (Facebook and Instagram) measure how our ads perform, using the Meta Pixel. Meta Platforms Ireland Ltd. receives the pages you visit and, when you confirm the email address of a new account, a "completed registration" event, together with browser identifiers and your IP address. Meta's automatic advanced matching also reads contact details you type into forms on our site, such as your email address or name, hashes them in your browser and sends them with these events so Meta can match them to a Facebook or Instagram account. Hashed details are still personal data. These events are sent from your browser and may also be forwarded to Meta through Meta's Conversions API Gateway. Our own server also sends page visits and completed-registration events directly to Meta's Conversions API, with your IP address, browser user agent and Meta browser identifiers, so Meta can count it once. To help Meta match these visits, your browser and our server also send a random visitor ID from our own cookie and, if you are signed in, your account ID, your confirmed email address and the name, city, postal code and country saved in your profile, all hashed first. We and Meta are joint controllers for collecting and sending this data, and Meta's further use, which may include processing in the USA, is described in the Meta Privacy Policy. When this is off, the Meta Pixel is not loaded and no page visit or registration event is sent to Meta. Together with analytics cookies, this choice also lets Google receive hashed contact details, as described under Analytics cookies.
Cookie
Purpose
Duration
_fbp
Identifies browsers for Meta ad measurement (Meta Pixel)
3 months
_fbc
Stores the Meta ad click that brought you here (Meta Pixel)
3 months
_bes_meid
Random visitor ID, sent to Meta only hashed, so your visits can be matched (Meta Pixel and Conversions API)